PROCEPT BioRobotics Q3 revenue $58.4M (+66% YoY); raises 2024 revenue and EBITDA guidance

PROCEPT BioRobotics Corp

2024-Q3 EPS reported -$1.41 revenue$156,262,000

Q3 revenue $58.4M, up 66% YoY; U.S. handpiece+consumables $29.6M (+74%).
Sold 45 U.S. systems at ~$432K ASP; install base reached 445 systems.
Record gross margin 63.2% vs 53.8% a year ago; net loss improved to $21.0M.
Adjusted EBITDA loss narrowed to $12.4M from $19.4M in Q3 2023.
Raised FY2024 revenue guidance to $222.5-223.0M (from $217M); adj. EBITDA loss guidance to ($60.0M) from ($67.5M).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.